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Abstract
In idiopathic pulmonary fibrosis (IPF), home monitoring experiences are limited, not yet real-time available nor
implemented in daily care. We evaluated feasibility and potential barriers of a new home monitoring program with
real-time wireless home spirometry in IPF. Ten patients with IPF were asked to test this home monitoring program,
including daily home spirometry, for four weeks. Measurements of home and hospital spirometry showed good
agreement. All patients considered real-time wireless spirometry useful and highly feasible. Both patients and
researchers suggested relatively easy solutions for the identified potential barriers regarding real-time home
monitoring in IPF.
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Introduction
Idiopathic pulmonary fibrosis (IPF) is a progressive, dev-
astating disease with a poor prognosis [1]. Symptoms as
increasing shortness of breath and immobility make
regular hospital visits a challenge for many patients.
New eHealth technologies hold great potential for re-
search and care by facilitating real-time, frequent data
collection at home. In IPF, home monitoring experiences
are limited and not yet implemented in daily care. Few
studies using daily handheld spirometry have been
performed in patients with IPF [2, 3]. These studies
showed that home spirometry in IPF is feasible, may
allow for better disease prediction and decrease sample
size for future trials [2, 3]. However, earlier studies using
home spirometry in interstitial lung diseases used
paper-based collection or central read-out of Forced
Vital Capacity (FVC) results [2–4]. This limits possibil-
ities to control quality of measurements, or respond
directly to FVC decline or non-adherence.
We assessed feasibility of a pre-developed home moni-
toring program in IPF [5], integrated with real-time,
wireless home spirometry. Furthermore, we evaluated
potential barriers and solutions for implementation of
wireless home spirometry in this mostly elderly patient
population.
Methods
This was a prospective pilot study at the Erasmus
Medical Center in 2017. Consecutive outpatients with
IPF were invited to participate. Approval of the Medical
ethics committee was obtained, and participants provided
written informed consent. Patients were asked to test the
home monitoring program “IPF-online” (http://www.ip-
fonline.nl) for four weeks on a tablet. IPF-online is a
secured online personal platform, following European
safety regulations. The program consists of daily home
spirometry, online patient-reported outcomes (PROs) at
baseline and after four weeks, weekly reporting of
side-effects and symptoms on visual analogue scales, an
information library, medication coach and eConsultations.
The bluetooth-enabled spirometer (MIR Spirobank Smart,
Italy) transmits data real-time via a secure encrypted con-
nection, enabling patients and healthcare providers to ac-
cess data directly (Fig. 1). The system generates email
alerts when patients report bothersome side-effects or
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FVC declines > 10% for three consecutive days. If patients
fail to perform spirometry or record symptoms, they
receive a reminder. Incorporated PROMs are King’s Brief
Interstitial Lung Disease health status questionnaire,
Hospital Anxiety and Depression Scale, Euroqol 5D-5 L
and an evaluation questionnaire [6–8]. At start, patients
received standardized instructions about the correct
use of home spirometry and the different components
of the online tool. Patients were considered trained
when they were able to perform three good, reprodu-
cible FVC measurements, with less than 150 ml dif-
ference in the two highest FVCs. Before start of the
study, potential barriers of the system were identified
based on literature and own experiences. At baseline,
potential barriers were discussed with patients. After
four weeks, their experiences and suggestions were
evaluated. Furthermore, patients performed hospital
spirometry at baseline and after four weeks.
Pearson correlation and Bland-Altman plots were used
to compare home with hospital spirometry, Wilcoxon
signed ranked test was used to compare baseline with
follow-up scores. Data are presented as mean (SD) or
median (range).
Results
Of 12 patients invited to participate, 10 patients were
included (9 men), with a mean age of 71 years (5). All
patients were on disease-modifying medication (60%
nintedanib, 40% pirfenidone). The mean FVC was 3.28 L
(1.04) or 79% of predicted (16).
Reliability of home spirometry
Measurements of home and hospital spirometry for FVC
(r = 0.94 (p < 0.001)) and FEV1 (r = 0.97 (p < 0.001)) were
highly correlated, and a Bland-Altman plot showed good
agreement (Fig. 2). Median difference between hospital
and home spirometry was 0.22 L (0.01-0.69 L) with over-
all lower readings for home spirometry. To evaluate
within-subject reproducibility, the median SD for 28
measurements was calculated (0.13 L (0.05 -0.39 L)).
The median coefficient of variation was 3.76% (3-12%).
Feasibility and potential barriers of home spirometry in
patients with IPF
The vast majority of patients considered daily spirometry
easy (80%) and not burdensome at all (90%), the other
patients were neutral. The mean adherence to home
Fig. 1 a Daily FVC in % predicted of one patient during two weeks. A star on top of the bar corresponds with a forced expiration > 6 s, and is
intended as extra motivation for patients. b Two examples of flow volume loops including daily remarks/advices
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spirometry was 98.8% (2.5). Most patients (80%) found it
pleasant to see their FVC results, 20% was neutral. All
patients considered real-time spirometry useful and
would recommend it to others, 90% wished to continue
home monitoring after the pilot: “It helps me feel more
in control”, “I like to monitor my own disease and be
monitored” and “I hope this program can replace out-
patient clinic visits in the future”. Daily home monitor-
ing did not lead to higher anxiety levels (HADS anxiety
score at baseline 4.5, score after 4 weeks 4.3, p = 0.57),
and quality of life remained stable (K-BILD total score at
baseline 59.2, score after 4 weeks 60.3, p = 0.65). Table 1
provides a comprehensive overview of potential barriers,
experiences and solutions for use of the home monitor-
ing system.
Discussion
This pilot study shows that a home monitoring program
integrated with real-time wireless home spirometry is
feasible in patients with IPF. In line with other
studies, home-based measurements were slightly lower
than hospital-based FVC, which may partly be
equipment-related, but also effort-related [2, 4]. We
tried to minimize the risk for ‘underperforming’ at
home by motivating patients through graphically
displaying their personal target value and prior
results, a six seconds countdown and advices to tech-
nically improve the measurements. However, home
and hospital readings are highly correlated and the
relative variability of home-based FVC is low, indicat-
ing that home spirometry is a reliable tool to monitor
patients at a distance. In a patient population with
progressive breathlessness and decreasing mobility
this enables close monitoring, while lowering the
burden of hospital visits, especially in countries with
long distances to the hospital. Moreover, real-time
uploading of results and automated email alerts not
only allow quality review of measurements, it also
enables real-time detection of FVC decline. For ex-
ample, we already observed a decrease in FVC two
days before a patient reported symptoms of a respira-
tory tract infection. Early detection may potentially
improve efficiency and quality of care for patients.
Besides spirometry, patients also recorded symptoms
and validated questionnaires online, which could be
important additional features for future studies.
All patients in our study supported the usefulness
of home monitoring, and appreciated being actively
involved in monitoring their disease. One patient
experienced technical problems with spirometry,
highlighting the importance of good instruction. No
effects on anxiety or quality of life were observed,
however, we believe that the duration of the study is
too short to draw definite conclusions on this. We
found no major barriers regarding use of real-time
wireless home spirometry; relatively easy solutions
were suggested by patients and investigators for po-
tential issues.
Fig. 2 Bland-Altman plot comparing hospital and home spirometry. The value for hospital FVC is the mean of the hospital-based FVC at baseline
and after four weeks. The value for home spirometry is the mean of 28 home FVC readings. The solid line represents the mean difference and
the dashed lines 95% limits of agreement (− 0.61 to 0.90 L).* This patient did not use the mouthpiece correctly leading to more variable and
higher readings compared to hospital spirometry
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A limitation of this study is that it is a single center
study, with 10 out of 12 consecutive patients willing
to participate. In the Netherlands, use of internet
amongst elderly people is rather high, however, also
in other countries internet use among people over the
age of 65 is steadily growing [9]. With worldwide in-
creasing internet use and technological advances, we
envision that relatively simple and low-cost systems
like this, will facilitate access to care and research for
a wider group of patients, also in remote areas and
lower socio-economic settings. Further limitations of
this pilot are the small sample size and short dur-
ation. Although this was sufficient to evaluate reliabil-
ity and potential barriers of a home monitoring
program with real-time wireless home spirometry, lar-
ger studies are required to assess whether it improves
care, allows for earlier detection of exacerbations, and
enhances data collection in clinical trials.
Conclusion
A home monitoring program including wireless home
spirometry, is highly feasible and appreciated by patients
with IPF, and enables real-time detection of change in
FVC and PROs facilitating personalized care.
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Table 1 A comprehensive overview of the identified potential barriers for use of the home monitoring system (wireless and
real-time), experiences from the pilot study, and possible solutions as suggested by patients and staff
Potential barriers for the use of real-time
home spirometry
Findings in our pilot experiment Possible solutions
No internet access Patient who never used internet before had
no problems using the tablet and perform
spirometry because of the simple design.
- Provide patients with a smartphone or tablet with
4G SIM card during study to guarantee internet access
- Use a simple application without too much information
Quality of measurements is difficult
to control
All patients performed mostly good quality
flow volume loops, which could be checked
real-time.
- New wireless spirometers have automated quality control
and provide advice to patients
- Use a device that shows a flow volume loop accessible
to patient and researchers to review quality
A handheld spirometer may be difficult
to use
A few patients had to get used to handheld
spirometry the first days.
Only one patient had variable results, due to
technical difficulties with the standard
mouthpiece. After providing an additional
mouthpiece the readings were comparable
to hospital readings.
- Provide a clear instruction manual and good training at
start of the study. Patients should be able to perform
3 good quality measurements with ≤150 ml difference in
the 2 highest FVC’s.
- Assess individual patients’ needs
- Consider using an extra/other mouthpiece
- Use a video consultation or clinic visit for refreshment
training
Motivation A 6 s countdown and FVC target value is
always shown during a forced expiration.
This motivated patients to blow as good
and long as possible.
- Do not use an FVC of 100% predicted as target value as
this might demotivate patients
- Provide an individual target value for each patient and
adjust target value during study if necessary
Home spirometry might induce coughing Some patients mentioned more urge to
cough compared to hospital spirometry, but
one measurement a day was not a problem
at all.
- Advise patients to perform spirometry after a period
of rest
- Advise patients to try again later that day when a
measurement failed because of coughing
Patients might get worried seeing their
own results
Anxiety and depression scores were not
higher after this short pilot. Almost all
patients considered it pleasant to see their
daily results.
- Incorporate automated email alerts to the researchers
and explain to patients that they will be contacted if FVC
declines significantly
- Provide an extra option that blinds patients from their
results
Daily home spirometry can be
bothersome to patients
None of the patients in the pilot considered
once daily spirometry bothersome, because
it was not time consuming and became part
of their routine.
- Advise patients to perform spirometry at almost the
same time every day to create a routine
- Explain that the whole process takes less than two
minutes
Compliance Patients got motivated by keeping track of
their own results and almost all patients
continued home spirometry after the pilot.
- Send patients email reminders when they do not
perform spirometry or report their symptoms
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